EFEMP1 and glioblastoma: An anti-fibulin-3 monoclonal antibody (mAb) targeting a 23 amino acid signalling epitope of the protein has been developed that successfully inhibits fibulin-3-mediated activation of key glioblastoma intracellular signalling pathways (Notch, NF-κB, ADAM17).